Sana Biotechnology, Inc. highlighted that Nature Biotechnology has published a paper titled "Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain." This paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) - the cells that give rise to the glial support cells of the brain - were transplanted into adult mice that had been neonatally transplanted with mutant Huntingtin (mHTT)-expressing hGPCs, the healthy cells outcompeted and eliminated the diseased glia, ultimately repopulating the brain with the healthy transplanted cells. These data establish an additional proof-of-concept for the development of SC379, Sana's pluripotent stem cell- derived GPC product candidate, as a potential therapy to deliver healthy allogeneic GPCs to patients with certain central nervous system disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.51 USD | +5.35% | -9.38% | +35.05% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.05% | 1.22B | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
-12.11% | 26.22B | |
+12.62% | 26.36B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- SANA Stock
- News Sana Biotechnology, Inc.
- Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions